Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
63 hedge funds and large institutions have $226M invested in Elevation Oncology in 2024 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 7 closing their positions.
1,526% more capital invested
Capital invested by funds: $13.9M → $226M (+$212M)
443% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 7
97% more funds holding
Funds holding: 32 → 63 (+31)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
29.49% more ownership
Funds ownership: 60.94% → 90.44% (+29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$12.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.9M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.9M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$7.7M |
| 5 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$7.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.52M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.32M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.97M |
| 4 |
O
OrbiMed
New York
|
-$1.81M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.52M |
ELEV Hedge Fund Activity: Q1 2024 in Review
63 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q1 2024, worth a combined $226M — up 1,526% from $13.9M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ELEV positions and 7 closed out — a net gain of 31 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $12.6M. The largest seller was Millennium Management, cutting an estimated $7.52M.
- 63 institutional investors held Elevation Oncology (ELEV) as of Q1 2024, up from 32 in Q4 2023.
- Funds reported $226M of Elevation Oncology stock for Q1 2024, up 1,526% quarter-over-quarter.
- 38 funds opened new Elevation Oncology positions in Q1 2024 and 7 closed out, a net change of +31 holders.
- The largest Elevation Oncology buyer in Q1 2024 was Farallon Capital Management, an estimated $12.6M added.
- The largest Elevation Oncology seller in Q1 2024 was Millennium Management, an estimated $7.52M sold.
Based on aggregated 13F filings for Q1 2024.